Prosecution Insights
Last updated: November 20, 2026
Application No. 18/012,453

DEVICE AND METHOD FOR DELIVERING ELECTROPORATION THERAPY

Final Rejection §102§103
Filed
Dec 22, 2022
Priority
Aug 26, 2020 — provisional 63/070,706 +1 more
Examiner
GUERRERO ROSARIO, ANA VERUSKA
Art Unit
3794
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Abbott Laboratories
OA Round
4 (Final)
44%
Grant Probability
Moderate
5-6
OA Rounds
1m
Est. Remaining
91%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
28 granted / 63 resolved
-25.6% vs TC avg
Strong +47% interview lift
Without
With
+46.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
39 currently pending
Career history
122
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
52.0%
+12.0% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
16.5%
-23.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 63 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment The Amendments filed August 24, 2026 have been entered. Currently, claims 1, 4, 6, and 15 have been amended, and claims 1-20 are pending in the application. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-4 and 7-13 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Stone (E.P. Application No. 2438877 B1). Regarding independent claim 1, Stone discloses an electroporation catheter (12) (pa. 0024, 0081 & Figs. 2-4) comprising: a shaft (combination of catheter body 14 and a series of structural struts or elements 54) (pa. 0031) having a longitudinal axis (20), a proximal end (16), and a distal end (18) (pa. 0024); and an electroporation assembly located at the distal end of the shaft (pa. 0025 & Fig. 4), the electroporation assembly having: at least a first electrode (50) and a second electrode (electrode on catheter body 14) configured to deliver RF ablation/electroporation pulses therebetween (when in a monopolar arrangement, pa. 0029, 0081); a non-conductive portion (combination of proximal portion 60 and distal portion 62 with proximal and distal barriers 66, 68) (pa. 0032-0033) having: a first end that encircles the longitudinal axis of the shaft and is connected to the shaft (see first ends of both the proximal portion and the distal portion with the smallest diameters, furthest from the first electrode, on Fig. 4); and a second end positioned radially outward from the first end (see second ends of both the proximal portion and the distal portion with the largest diameters, closest to the first electrode, on Fig. 4), wherein the non-conductive portion forms a wall of non-conductive material that spans between the first end and the second end (pa. 0035); wherein the first electrode is located adjacent to the first end of the non- conductive portion and radially inward of the second end of the non-conductive portion (see Fig. 4); and wherein at least a portion of the wall of the non-conductive material is interposed between the first electrode and the second electrode to prevent formation of a low-impedance path between the first electrode and the second electrode that does not include tissue to be treated (due to the non-conductive portion comprising a braided Nitinol wire coated in silicone or simply comprising a polyurethane or PTFE material; pa. 0035), such that a conductive path formed between the first electrode and the second electrode includes tissue located adjacent the non-conductive portion (pa. 0029 & Fig. 4). Examiner will be interpreting claim language such as “electroporation catheter” and “electroporation assembly” as a functional recitation of the intended use of the first and the second electrodes on the catheter. It has been held that a functional recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In the instant case, the first electrode and the second electrode of Stone readily provides for such functionality given that they are able to provide RF energy as either a single pulse or multiple pulses of varying durations, wherein the energy can be delivered in any combination of amplitude and frequency from any combination of electrodes (pa. 0081). Therefore, both electrodes are capable of providing electroporation therapy; thereby, meeting the claim limitation. Regarding claim 2, Stone discloses wherein the non-conductive portion is cone- shaped having an apex at the first end connected to the shaft (pa. 0035 & Fig. 4). Regarding claim 3, Stone discloses wherein the non-conductive portion extends away from the shaft in a distal direction from the first end to the second end (see Fig. 4). Regarding claim 4, Stone discloses wherein the first electrode and the second electrode are located on the shaft and the first end of the non-conductive portion is connected to the shaft between the first electrode and the second electrode (pa. 0029). Regarding claim 7, Stone discloses wherein the non-conductive portion is a sleeve (see Fig. 4). Regarding claim 8, Stone discloses wherein the non-conductive portion is movable between an undeployed state and a deployed state, wherein a radius of the non-conductive portion is greater in the deployed state (pa. 0025, 0033 & Figs. 7A-7E). Regarding claim 9, Stone discloses wherein the non-conductive portion is passively deployed via removal of a sheath (a restraining sheath) located on an outer periphery of the non-conductive portion (pa. 0031). Regarding claim 10, Stone discloses wherein the non-conductive portion is actively deployed via a mechanism having a first end coupled to the electroporation assembly and a second end connected to a handle (28) located on the proximal end of the shaft (pa. 0031). Regarding claim 11,Stone discloses wherein the non-conductive portion comprises a compliant non-conductive material (pa. 0035). Regarding claim 12, Stone discloses wherein the non-conductive portion comprises a memory shape material (i.e., Nitinol) (pa. 0035). Regarding claim 13, Stone discloses wherein the compliant, non-conductive portion comprises one or more silicone, polyurethane, rubber, and/or a non-conductive polymer (pa. 0035). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 14 is rejected under 35 U.S.C. 103 as being unpatentable over Stone as applied to claim 1 above, and further in view of Jackson (W.O. Application No. 2007044244 A2). Regarding claim 14, Stone discloses the invention substantially as claimed in claim 1 discussed above. However, Stone does not disclose the non-conductive portion comprises a non-compliant material. Jackson, in the same field of endeavor, teaches an expandable, non-compliant insulative member (28) with a plurality of electrodes (32) suitable to contact the tissue to apply ablation treatment (pa. 0080-0082). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have substituted the compliant non-conductive material of the non-conductive portion of Stone with a non-compliant material as taught by Jackson in order to allow for precise control and consistent force application. Claims 15-20 are rejected under 35 U.S.C. 103 as being unpatentable over Stone (E.P. Application No. 2438877 B1), and further in view of Neal (U.S. Patent No. 10702326 B2). Regarding independent claim 15, Stone discloses a method of delivering intermittent bursts/pulses of RF energy to a patient (pa. 0081), specifically for the purpose of remodeling or removing plaques and other occlusive materials in order to improve blood flow (pa. 0014), the method comprising: introducing a catheter (12) into the patient (pa. 0013, 0024 & Figs. 1-4) the catheter including a shaft (combination of catheter body 14 and a series of structural struts or elements 54) (pa. 0031) having a proximal end (16) attached to a handle (28) (pa. 0019, 0025) and a distal end (18) that includes an ablation assembly (pa. 0024-0025 & Fig. 4); navigating the ablation assembly in an undeployed state to a desired tissue site (pa. 0035 & Fig. 7A), wherein the electroporation assembly includes at least a first electrode (50) (pa. 0024), a second electrode (electrode on catheter body 14) (pa. 0029), and a cone-shaped non-conductive portion (combination of proximal portion 60 and distal portion 62 with proximal and distal barriers 66, 68) (pa. 0032-0033) attached on a first end (see first ends of both the proximal portion and the distal portion with the smallest diameters, furthest from the first electrode, on Fig. 4) to the shaft, wherein the cone shaped non-conductive portion terminates in a free distal edge (see second ends of both the proximal portion and the distal portion with the largest diameters, closest to the first electrode, on Fig. 4), and wherein the first electrode is located adjacent to the first end of the non-conductive portion and radially inward of the free distal edge of the non-conductive portion (see Fig. 4), and wherein at least a portion of the cone shaped non-conductive portion is interposed between the first electrode and the second electrode to prevent formation of a low-impedance path between the first and second electrodes that does not include tissue at the desired tissue site (pa. 0029 & Fig. 4); deploying the ablation assembly, wherein deployment of the ablation assembly includes allowing the free distal edge of the non-conductive portion to extend radially outward so that at least the free distal edge is brought into contact with the desired tissue site (pa. 0035 & Fig. 7B); and delivering ablation energy/RF pulses between the first electrode and the second electrode (in a monopolar arrangement), such that a conductive path formed between the first and second electrodes includes tissue located adjacent the cone shaped non-conductive portion (pa. 0029, 0081, 0053). However, Stone does not explicitly disclose the catheter providing electroporation therapy. Neal, in the same field of endeavor, teaches a method of inserting an irreversible electroporation (IRE) device into a blood vessel in order to ablate all or a portion of growth (i.e., plaque buildup) within the vessel that is obstructing blood flow (Col. 14, lines 28-42). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have incorporated the electroporation modality of the IRE device of Stewart into the device of Stone since both methods of energy therapy are known variants in the art and they would both yield the same predictable results of removing plaque from a vessel in order to increase the blood flow. Regarding claim 16, Stone/Neal combination discloses wherein the ablation assembly is passively deployed by removing a sheath (a restraining sheath) surrounding the non-conductive portion of the electroporation assembly (Stone, pa. 0031). Regarding claim 17, Stone/Neal combination discloses wherein the ablation assembly is actively deployed by activating a mechanism in the handle to cause the free distal edge of the non-conductive portion to expand radially outward (Stone, pa. 0031). Regarding claim 18, Stone/Neal combination discloses wherein the free distal edge of the non-conductive portion is brought into contact with the tissue to be treated, wherein the tissue to be treated is approximately planar (Stone, pa. 0067 & Figs. 7B). Examiner will be interpreting the claim language of “wherein the tissue to be treated is approximately planar” as a functional recitation of the intended use of the electroporation assembly. It has been held that a functional recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In the instant case, ablation assembly of Stone readily provides for such functionality providing treatment to tissue of a patient, regardless of the shape. Therefore, the prior art meets the claim limitation. Regarding claim 19, Stone/Neal combination discloses wherein an outer surface of the non-conductive portion is brought into contact with the tissue to be treated, wherein the tissue to be treated is tubular (Stone, pa. 0067 & Figs. 7B). Regarding claim 20, Stone discloses a method of delivering intermittent bursts/pulses of RF energy to a patient (pa. 0081). However, Stone does not explicitly disclose the catheter providing irreversible electroporation therapy. Neal, in the same field of endeavor, teaches a method of inserting an irreversible electroporation (IRE) device into a blood vessel in order to ablate all or a portion of growth (i.e., plaque buildup) within the vessel that is obstructing blood flow (Col. 14, lines 28-42). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have incorporated the electroporation modality of the IRE device of Stewart into the device of Stone since both methods of energy therapy are known variants in the art and they would both yield the same predictable results of removing plaque from a vessel in order to increase the blood flow. Response to Arguments Applicant' s arguments, see pages 6-8 of the Remarks filed 08/24/2026, with respect to the rejection of independent claims 1 and 15 under 35 U.S.C. 103 as unpatentable over Basu in view of Stewart have been fully considered and are persuasive. Specifically, Applicant’s amendments to the claim to further require wherein at least a portion of the wall of the non-conductive material is interposed between the first electrode and the second electrode to prevent formation of a low-impedance path between the first electrode and the second electrode that does not include tissue to be treated is defined over Basu and Stewart given that they do not contemplate this claimed feature. Therefore, the prior rejections has been withdrawn. However, upon further consideration, the following new grounds of rejection have been set forth in the action above: Claims 1-4 and 7-13 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Stone (E.P. Application No. 2438877 B1). Claim 14 is rejected under 35 U.S.C. 103 as being unpatentable over Stone as applied to claim 1 above, and further in view of Jackson (W.O. Application No. 2007044244 A2). Claims 15-20 are rejected under 35 U.S.C. 103 as being unpatentable over Stone (E.P. Application No. 2438877 B1), and further in view of Neal (U.S. Patent No. 10702326 B2). It is the Examiner’s position that the newly filed rejections based on the combination is tenable for at least the reasoning set forth in the action above. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANA VERUSKA GUERRERO ROSARIO whose telephone number is (571)272-6976. The examiner can normally be reached Monday - Thursday 7:00 - 4:30 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Stoklosa can be reached at (571) 272-1213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.V.G./Examiner, Art Unit 3794 /Ronald Hupczey, Jr./Primary Examiner, Art Unit 3794
Read full office action

Prosecution Timeline

Show 2 earlier events
Oct 28, 2025
Response Filed
Jan 26, 2026
Final Rejection mailed — §102, §103
Mar 26, 2026
Response after Non-Final Action
Apr 27, 2026
Request for Continued Examination
Apr 29, 2026
Response after Non-Final Action
Jun 01, 2026
Non-Final Rejection mailed — §102, §103
Aug 24, 2026
Response Filed
Nov 02, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758152
Contact Quality System and Method
4y 9m to grant Granted Oct 13, 2026
Patent 12721535
PULSE TRANSIT TIME MEASUREMENT DEVICE AND BLOOD PRESSURE MEASUREMENT DEVICE
5y 6m to grant Granted Sep 01, 2026
Patent 12667415
BASKET CATHETER WITH CLOVERLEAF STRUCTURE TO PROVIDE PREDETERMINED LATERAL STIFFNESS AND AXIAL STRAIN
3y 3m to grant Granted Jun 30, 2026
Patent 12642574
MEDICAL INSTRUMENT CUTTING SYSTEMS AND METHODS
5y 1m to grant Granted Jun 02, 2026
Patent 12622738
MEDICAL DEVICES AND RELATED METHODS
4y 11m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
44%
Grant Probability
91%
With Interview (+46.7%)
4y 0m (~1m remaining)
Median Time to Grant
High
PTA Risk
Based on 63 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month